The expiration of patents for "blockbuster" biologics has opened the door for biosimilars—essentially generic versions of complex proteins. However, unlike small-molecule generics, biosimilars are not identical to the original drug; they are "highly similar." Because the manufacturing process is unique to each company, the host cell protein profile of a biosimilar can be very different...
Portuguese (Brazil) 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Tiếng Việt